Dashboard
Manage Tickers

GLPG GALAPAGOS NV

Nasdaq glpg.com


$ 30.97 $ -0.42 (-1.34 %)    

Wednesday, 29-Oct-2025 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 634.74 $ 2.85 (0.45 %)
DIA $ 476.09 $ -0.78 (-0.16 %)
SPY $ 686.84 $ 0.33 (0.05 %)
TLT $ 90.87 $ -0.93 (-1.01 %)
GLD $ 363.50 $ -1.38 (-0.38 %)
$ 30.92
$ 31.48
$ 30.50 x 13
$ 33.42 x 100
$ 30.92 - $ 31.61
$ 22.36 - $ 37.78
108,130
na
2.04B
$ 0.62
$ 13.57
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

galapagos-nv-to-present-new-in-vitro-pharmacological-data-on-its-selective-tyk2-inhibitor-glpg3667-at-acr-convergence-2025-conference-in-chicago-from-october-2429-2025
Galapagos NV To Present New In Vitro Pharm...
10/23/2025 20:10:17

Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new in vitro pharmacological data from its sel...

rbc-capital-maintains-sector-perform-on-galapagos-raises-price-target-to-28
RBC Capital Maintains Sector Perform on Ga...
10/22/2025 14:17:27

RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from ...

leerink-partners-upgrades-galapagos-to-outperform-raises-price-target-to-40
Leerink Partners Upgrades Galapagos to Out...
10/21/2025 20:43:27

Leerink Partners analyst Faisal Khurshid upgrades Galapagos (NASDAQ:GLPG) from Market Perform to Outperform and raises the p...

paccar-posts-downbeat-earnings-joins-neuphoria-therapeutics-citius-pharmaceuticals-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
PACCAR Posts Downbeat Earnings, Joins Neup...
10/21/2025 12:16:10

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/21/2025 12:10:04

why-crown-holdings-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket
Why Crown Holdings Shares Are Trading High...
10/21/2025 09:46:14

galapagos-plans-to-wind-down-cell-therapy-business-and-redirect-cash-toward-transformational-deals
Galapagos Plans To Wind Down Cell Therapy ...
10/21/2025 06:00:47

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support ...

galapagos-says-as-of-todays-date-the-board-has-received-a-limited-number-of-non-binding-offers-from-consortia-predominantly-comprised-of-financial-investors-to-acquire-the-cell-therapy-business
Galapagos Says As Of Today's Date, The Boa...
10/01/2025 20:03:40

galapagos-nv-advances-cell-therapy-business-divestment-review-expects-decision-by-november-5-2025
Galapagos NV Advances Cell Therapy Busines...
10/01/2025 20:02:59

Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and its Board of Directors today iss...

galapagos-receives-fda-rmat-designation-for-glpg5101-as-anti-cd194-1bb-car-t-therapy-targeting-relapsedrefractory-mantle-cell-lymphoma
Galapagos Receives FDA RMAT Designation Fo...
08/06/2025 06:39:21

tesla-posts-downbeat-earnings-joins-community-health-systems-chipotle-mexican-grill-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Tesla Posts Downbeat Earnings, Joins Commu...
07/24/2025 12:36:13

why-alphabet-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why Alphabet Shares Are Trading Higher; He...
07/24/2025 09:23:22

galapagos-q2-eps-145-misses-009-estimate-sales-86330m-beat-71332m-estimate
Galapagos Q2 EPS $(1.45) Misses $(0.09) Es...
07/23/2025 20:20:49

Galapagos (NASDAQ:GLPG) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(0.09) b...

Core News & Articles
Earnings Scheduled For July 23, 2025
07/23/2025 08:32:26

galapagos-appoints-aaron-cox-as-chief-financial-officer-effective-july-7
Galapagos Appoints Aaron Cox As Chief Fina...
06/23/2025 06:35:51

galapagos-reports-97-complete-response-rate-with-glpg5101-in-phase-12-atalanta-1-trial-for-relapsedrefractory-inhl
Galapagos Reports 97% Complete Response Ra...
06/18/2025 20:02:51

Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CA...

galapagos-reports-safety-data-from-atalanta-1-phase-12-study-of-cd19-car-t-therapy-in-relapsedrefractory-nhl-highlighting-low-high-grade-toxicity-95-use-of-fresh-cells-and-rapid-7-day-turnaround-enabled-by-decentralized-manufacturing
Galapagos Reports Safety Data From ATALANT...
06/12/2025 20:02:00

galapagos-announces-new-data-from-atalanta-1-study-of-investigational-car-t-candidate-glpg5101
Galapagos Announces New Data From ATALANTA...
05/14/2025 20:05:07

galapagos-re-evaluates-proposed-separation-amid-regulatory-and-market-shifts-explores-strategic-alternatives-for-cell-therapy-business-henry-gosebruch-named-galapagos-ceo
Galapagos Re-Evaluates Proposed Separation...
05/13/2025 05:51:14

Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments...

galapagos-q1-2025-gaap-eps-247-down-from-152-yoy-sales-78867m-up-from-67805m-yoy
Galapagos Q1 2025 GAAP EPS $(2.47) Down Fr...
04/23/2025 20:07:07

Galapagos (NASDAQ:GLPG) reported quarterly losses of $(2.47) per share. This is a 262.57 percent decrease over earnings of $1.5...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION